Idorsia Ltd (0RQE) Price & Analysis

Compare

4 Followers

0RQE Stock Chart & Stats

CHF3.27

-CHF0.84(-6.89%)

At close: Jul 22 4:00 PM EDT

CHF3.27

-CHF0.84(-6.89%)

Day’s Range― - ―

52-Week RangeCHF0.63 - CHF4.83

Previous CloseN/A

Volume1.66K

Average Volume (3M)510.70K

Market Cap

CHF869.88M

Enterprise ValueCHF1.66B

Total Cash (Recent Filing)CHF82.16M

Total Debt (Recent Filing)CHF1.30B

Price to Earnings (P/E)―

Beta3.19

Next Earnings

Feb 26, 2026

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding249,232,670

10 Day Avg. Volume952,249

30 Day Avg. Volume510,700

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF3.40

Price Target Upside3.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Global ExpansionGlobal expansion of QUVIVIQ continues, as Simcere is in the process of introducing the product in China, opening an additional royalty stream for Idorsia.

Path To ProfitabilityThe company has outlined a path to profitability driven by the uptake of daridorexant in European and Canadian markets.

Regulatory ProgressAprocitentan is approved in Europe and the United Kingdom under the trade name JERAYGO and in the United States under the trade name TRYVIO™, indicating broad regulatory acceptance.

Bears Say

Approval DelaysRisks include failure of late-stage candidates in pivotal trials and inability to obtain timely approval of key assets.

Strategic SupportRisks include, but are not limited to: failure of late-stage candidates in pivotal trials, inability to obtain timely approval of key assets, lack of sufficient support from strategic partners, setbacks with earlier-stage candidates, and possible near- to medium-term dilution risk.

Trial FailuresRisks include the failure of late-stage candidates in pivotal trials and inability to obtain timely approval of key assets.

Idorsia Ltd News

Idorsia Ltd’s Strengthened Financial Position and Growth Prospects Justify Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Idorsia Ltd today and set a price target...

12d ago

Idorsia’s Growth Potential Bolstered by Aprocitentan Approval and Strategic Commercialization Efforts

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with...

2M ago

Idorsia upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF...

2M ago

Idorsia price target raised to CHF 2 from CHF 1 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Idorsia (IDRSF) to CHF 2 from CHF 1 and keeps...

3M ago

Idorsia Ltd Earnings Call: Strong Growth Amid Challenges

Idorsia Ltd (($CH:IDIA)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

Idorsia Ltd Earnings Call: Balancing Challenges and Growth

Idorsia Ltd (($CH:IDIA)) has held its Q4 earnings call. Read on for the main highlights of the call....

8M ago

Idorsia upgraded to Hold from Sell at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis upgraded Idorsia (IDRSF) to Hold from Sell with an unchanged price target of...

1y ago

Idorsia rating suspended at Goldman Sachs

Goldman Sachs analyst Rajan Sharma suspended the firm’s investment rating, price target and earnings estimates for Idorsia (IDRSF)...

1y ago

Idorsia price target lowered to CHF 1.20 from CHF 2 at JPMorgan

JPMorgan lowered the firm’s price target on Idorsia (IDRSF) to CHF 1.20 from CHF 2 and keeps a...

1y ago

Idorsia price target lowered to CHF 1 from CHF 4 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Idorsia to CHF 1 from CHF 4 and keeps an...

2y ago

Idorsia upgraded to Hold from Reduce at Kepler Cheuvreux

Kepler Cheuvreux upgraded Idorsia to Hold from Reduce with a CHF 1.80 price target. Published first on TheFly...

2y ago

VTRS Earnings: Viatris’ Revenue Declines in Q4; Boosts Buybacks

Viatris (NASDAQ:VTRS) shares are in focus today after the global healthcare major announced its results for the fourth...

2y ago

VTRS

Idorsia price target lowered by CHF 4.50 at JPMorgan

JPMorgan lowered the firm’s price target on Idorsia to CHF 2 from CHF 6.50 and keeps a Neutral...

2y ago

Idorsia downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Idorsia to Neutral from Buy with a price target of CHF 2, down from CHF...

2y ago

0RQE FAQ

What was Idorsia Ltd’s price range in the past 12 months?

Idorsia Ltd lowest share price was CHF0.63 and its highest was CHF4.83 in the past 12 months.

What is Idorsia Ltd’s market cap?

Idorsia Ltd’s market cap is CHF869.88M.

When is Idorsia Ltd’s upcoming earnings report date?

Idorsia Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 110 days.

How were Idorsia Ltd’s earnings last quarter?

Idorsia Ltd released its earnings results on Oct 30, 2025. The company reported -CHF0.37 earnings per share for the quarter, missing the consensus estimate of -CHF0.22 by -CHF0.15.

Is Idorsia Ltd overvalued?

According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Idorsia Ltd pay dividends?

Idorsia Ltd does not currently pay dividends.

What is Idorsia Ltd’s EPS estimate?

Idorsia Ltd’s EPS estimate is -0.21.

How many shares outstanding does Idorsia Ltd have?

Idorsia Ltd has 249,232,670 shares outstanding.

What happened to Idorsia Ltd’s price movement after its last earnings report?

Idorsia Ltd reported an EPS of -CHF0.37 in its last earnings report, missing expectations of -CHF0.22. Following the earnings report the stock price went down -3.348%.

Which hedge fund is a major shareholder of Idorsia Ltd?

Currently, no hedge funds are holding shares in GB:0RQE

Company Description

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd (0RQE) Earnings & Revenues

Historic Earnings Reports

0RQE Stock 12 Month Forecast

Average Price Target

CHF3.40

▲(3.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"CHF1","3":"CHF3","5":"CHF5","7":"CHF7","-1":"-CHF1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF3.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.463,3.658153846153846,3.8533076923076925,4.048461538461538,4.243615384615385,4.438769230769231,4.633923076923077,4.829076923076923,5.024230769230769,5.219384615384616,5.414538461538461,5.609692307692308,5.804846153846154,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.463,3.4581538461538464,3.453307692307692,3.4484615384615385,3.4436153846153847,3.4387692307692306,3.433923076923077,3.429076923076923,3.4242307692307694,3.4193846153846152,3.4145384615384615,3.409692307692308,3.4048461538461536,{"y":3.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.463,3.3504615384615386,3.237923076923077,3.1253846153846156,3.0128461538461537,2.9003076923076923,2.7877692307692308,2.6752307692307693,2.562692307692308,2.450153846153846,2.3376153846153844,2.225076923076923,2.1125384615384615,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.964,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.812,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.705,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.042,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.319,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.621,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.747,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.361,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.463,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >